Skip to main content
. 2021 Feb 25;13:1967–1979. doi: 10.2147/CMAR.S287386

Figure 1.

Figure 1

CAR10 is upregulated and associated with a poor prognosis in patients with NSCLC. (A and B) Expression of CAR10 in 50 NSCLC and paired ANT samples was measured using RT-qPCR. ****P<0.0001. CAR10 expression in NSCLC and normal lung tissues or ANTs was analyzed in the (C) GSE19188, (D) GSE30219 and (E) GSE118370 datasets. (F) CAR10 was highly expressed in patients with lymph node metastasis (N1 and N2) compared with those without (N0). **P<0.01 and ##P<0.01 vs the N0 and N1 groups, respectively. (G) Kaplan-Meier analysis was conducted to determine OS time in the patients with NSCLC and high or low CAR10 expression levels; P=0.0006. (H) The CAR10 expression in a normal human bronchial epithelial cell line (16HBE) and in the A549, H1975, SPCA1 and H1299 NSCLC cell lines was determined using RT-qPCR. ***P<0.001. The data are presented as the mean ± SD from three independent experiments.

Abbreviations: CAR10, chromatin-associated RNA Intergenic 10; NSCLC, non-small cell lung cancer; RT-qPCR, reverse transcription-quantitative PCR; ANT, adjacent normal tissue; OS, overall survival.